Similar frequency of autoantibodies against pneumocytes type II and Clara cells in patients with interstitial lung diseases and healthy persons

1991 ◽  
Vol 69 (7) ◽  
pp. 297-302 ◽  
Author(s):  
R. Erlinger ◽  
G. Rauh ◽  
J. Behr ◽  
U. Schumacher ◽  
U. Welsch ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Type Ii ◽  
Clara Cells ◽  
Similar Frequency ◽  
Pneumocytes Type Ii ◽  
Healthy Persons

Relapsing poly(peri)chondritis associated with fibrosing alveolar disease and antibodies to pneumocytes type II and clara cells

1989 ◽  
Vol 67 (15) ◽  
pp. 784-789 ◽  
Author(s):  
G. Rauh ◽  
H. Dörfler ◽  
R. Erlinger ◽  
K. G. Riedel ◽  
N. Zöllner
Keyword(s):  
Type Ii ◽  
Clara Cells ◽  
Pneumocytes Type Ii

Lung ultrasound in the evaluation of interstitial lung diseases

2016 ◽  
Vol 37 (S 01) ◽  
Author(s):  
N Buda ◽  
M Piskunowicz ◽  
M Porzezińska ◽  
W Kosiak ◽  
Z Zdrojewski
Keyword(s):  
Lung Diseases ◽  
Lung Ultrasound ◽  
Interstitial Lung Diseases

Characteristics of the immune and cytokine status in patients with interstitial lung diseases

2018 ◽  
Vol 1 (1) ◽  
pp. 25-29
Author(s):  
Mirgolib RAКHIMOV ◽  
◽  
Nematilla ARALOV ◽  
Shukhrat Ziyadullaev
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases

Value of Thoracoscopic Lung Biopsy in Diagnosis of Diffuse Interstitial Lung Diseases

2018 ◽  
Vol 86 (6) ◽  
pp. 1159-1163
Author(s):  
ISMAEIL A. ATTIA, M.D.; MOHAMED S. AL-HAKIM, M.D. ◽  
KHALED M.I. HALIMA, M.D.; MOAZ A.E. ABD EL-ATI, M.Sc.
Keyword(s):  
Lung Biopsy ◽  
Lung Diseases ◽  
Interstitial Lung Diseases

scholarly journals Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale

2020 ◽  
Vol 201 (2) ◽  
pp. 260-261
Author(s):  
Arnaud Bourdin ◽  
Carey M. Suehs ◽  
Thomas V. Colby ◽  
Isabelle Vachier ◽  
Nicolas Molinari ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases

scholarly journals Cellular Senescence in Lung Fibrosis

2021 ◽  
Vol 22 (13) ◽  
pp. 7012
Author(s):  
Fernanda Hernandez-Gonzalez ◽  
Rosa Faner ◽  
Mauricio Rojas ◽  
Alvar Agustí ◽  
Manuel Serrano ◽  
...  
Keyword(s):  
Cell Fate ◽  
Cellular Senescence ◽  
Lung Fibrosis ◽  
Lung Diseases ◽  
Physiological Mechanism ◽  
Lung Parenchyma ◽  
Scar Tissue ◽  
Interstitial Lung Diseases ◽  
Cellular Damage ◽  
Age Related

Fibrosing interstitial lung diseases (ILDs) are chronic and ultimately fatal age-related lung diseases characterized by the progressive and irreversible accumulation of scar tissue in the lung parenchyma. Over the past years, significant progress has been made in our incomplete understanding of the pathobiology underlying fibrosing ILDs, in particular in relation to diverse age-related processes and cell perturbations that seem to lead to maladaptation to stress and susceptibility to lung fibrosis. Growing evidence suggests that a specific biological phenomenon known as cellular senescence plays an important role in the initiation and progression of pulmonary fibrosis. Cellular senescence is defined as a cell fate decision caused by the accumulation of unrepairable cellular damage and is characterized by an abundant pro-inflammatory and pro-fibrotic secretome. The senescence response has been widely recognized as a beneficial physiological mechanism during development and in tumour suppression. However, recent evidence strengthens the idea that it also drives degenerative processes such as lung fibrosis, most likely by promoting molecular and cellular changes in chronic fibrosing processes. Here, we review how cellular senescence may contribute to lung fibrosis pathobiology, and we highlight current and emerging therapeutic approaches to treat fibrosing ILDs by targeting cellular senescence.

Sign in / Sign up

Export Citation Format

Share Document